No significant benefit of moderate-dose vitamin C on severe COVID-19 cases

There is no specific drug for coronavirus disease 2019 (COVID-19). We aimed to investigate the possible clinical efficacy of moderate-dose vitamin C infusion among inpatients with severe COVID-19. Data of 397 adult patients with severe COVID-19 admitted to a designated clinical center of Wuhan Union...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zheng Shaoping, Chen Qiaosen, Jiang Hongbo, Guo Chunxia, Luo Jinzhuo, Li Sumeng, Wang Hua, Li Huadong, Zheng Xin, Weng Zhihong
Formato:	article
Lenguaje:	EN
Publicado:	De Gruyter 2021
Materias:	sars-cov-2 covid-19 vitamin c Medicine R
Acceso en línea:	https://doaj.org/article/5417170dbca341d691b37fd4420b6f22
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5417170dbca341d691b37fd4420b6f22
record_format	dspace
spelling	oai:doaj.org-article:5417170dbca341d691b37fd4420b6f222021-12-05T14:10:55ZNo significant benefit of moderate-dose vitamin C on severe COVID-19 cases2391-546310.1515/med-2021-0361https://doaj.org/article/5417170dbca341d691b37fd4420b6f222021-09-01T00:00:00Zhttps://doi.org/10.1515/med-2021-0361https://doaj.org/toc/2391-5463There is no specific drug for coronavirus disease 2019 (COVID-19). We aimed to investigate the possible clinical efficacy of moderate-dose vitamin C infusion among inpatients with severe COVID-19. Data of 397 adult patients with severe COVID-19 admitted to a designated clinical center of Wuhan Union Hospital (China) between February 13 and February 29, 2020, were collected. Besides standard therapies, patients were treated with vitamin C (2–4 g/day) or not. The primary outcome was all-cause death. Secondary outcome was clinical improvement of 2 points on a 6-point ordinal scale. About 70 participants were treated with intravenous vitamin C, and 327 did not receive it. No significant association was found between vitamin C use and death on inverse probability treatment weighting (IPTW) analysis (weighted hazard ratio [HR], 2.69; 95% confidence interval [CI], 0.91–7.89). Clinical improvement occurred in 74.3% (52/70) of patients in the vitamin C group and 95.1% (311/327) in the no vitamin C group. No significant difference was observed between the two groups on IPTW analysis (weighted HR, 0.76; 95% CI, 0.55–1.07). Our findings revealed that in patients with severe COVID-19, treatment with moderate dose of intravenous vitamin C had no significant benefit on reducing the risk of death and obtaining clinical improvement.Zheng ShaopingChen QiaosenJiang HongboGuo ChunxiaLuo JinzhuoLi SumengWang HuaLi HuadongZheng XinWeng ZhihongDe Gruyterarticlesars-cov-2covid-19vitamin cMedicineRENOpen Medicine, Vol 16, Iss 1, Pp 1403-1414 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	sars-cov-2 covid-19 vitamin c Medicine R
spellingShingle	sars-cov-2 covid-19 vitamin c Medicine R Zheng Shaoping Chen Qiaosen Jiang Hongbo Guo Chunxia Luo Jinzhuo Li Sumeng Wang Hua Li Huadong Zheng Xin Weng Zhihong No significant benefit of moderate-dose vitamin C on severe COVID-19 cases
description	There is no specific drug for coronavirus disease 2019 (COVID-19). We aimed to investigate the possible clinical efficacy of moderate-dose vitamin C infusion among inpatients with severe COVID-19. Data of 397 adult patients with severe COVID-19 admitted to a designated clinical center of Wuhan Union Hospital (China) between February 13 and February 29, 2020, were collected. Besides standard therapies, patients were treated with vitamin C (2–4 g/day) or not. The primary outcome was all-cause death. Secondary outcome was clinical improvement of 2 points on a 6-point ordinal scale. About 70 participants were treated with intravenous vitamin C, and 327 did not receive it. No significant association was found between vitamin C use and death on inverse probability treatment weighting (IPTW) analysis (weighted hazard ratio [HR], 2.69; 95% confidence interval [CI], 0.91–7.89). Clinical improvement occurred in 74.3% (52/70) of patients in the vitamin C group and 95.1% (311/327) in the no vitamin C group. No significant difference was observed between the two groups on IPTW analysis (weighted HR, 0.76; 95% CI, 0.55–1.07). Our findings revealed that in patients with severe COVID-19, treatment with moderate dose of intravenous vitamin C had no significant benefit on reducing the risk of death and obtaining clinical improvement.
format	article
author	Zheng Shaoping Chen Qiaosen Jiang Hongbo Guo Chunxia Luo Jinzhuo Li Sumeng Wang Hua Li Huadong Zheng Xin Weng Zhihong
author_facet	Zheng Shaoping Chen Qiaosen Jiang Hongbo Guo Chunxia Luo Jinzhuo Li Sumeng Wang Hua Li Huadong Zheng Xin Weng Zhihong
author_sort	Zheng Shaoping
title	No significant benefit of moderate-dose vitamin C on severe COVID-19 cases
title_short	No significant benefit of moderate-dose vitamin C on severe COVID-19 cases
title_full	No significant benefit of moderate-dose vitamin C on severe COVID-19 cases
title_fullStr	No significant benefit of moderate-dose vitamin C on severe COVID-19 cases
title_full_unstemmed	No significant benefit of moderate-dose vitamin C on severe COVID-19 cases
title_sort	no significant benefit of moderate-dose vitamin c on severe covid-19 cases
publisher	De Gruyter
publishDate	2021
url	https://doaj.org/article/5417170dbca341d691b37fd4420b6f22
work_keys_str_mv	AT zhengshaoping nosignificantbenefitofmoderatedosevitaminconseverecovid19cases AT chenqiaosen nosignificantbenefitofmoderatedosevitaminconseverecovid19cases AT jianghongbo nosignificantbenefitofmoderatedosevitaminconseverecovid19cases AT guochunxia nosignificantbenefitofmoderatedosevitaminconseverecovid19cases AT luojinzhuo nosignificantbenefitofmoderatedosevitaminconseverecovid19cases AT lisumeng nosignificantbenefitofmoderatedosevitaminconseverecovid19cases AT wanghua nosignificantbenefitofmoderatedosevitaminconseverecovid19cases AT lihuadong nosignificantbenefitofmoderatedosevitaminconseverecovid19cases AT zhengxin nosignificantbenefitofmoderatedosevitaminconseverecovid19cases AT wengzhihong nosignificantbenefitofmoderatedosevitaminconseverecovid19cases
_version_	1718371603844169728

No significant benefit of moderate-dose vitamin C on severe COVID-19 cases

Ejemplares similares